December 12, 2022 06:41 PM ESTUpdated December 13, 06:43 AM

Updated: FDA approves Mirati's KRAS drug in non-small cell lung cancer

Kyle LaHucik

Senior Reporter

Paul Schloesser

Associate Editor

FDA granted accelerated approval to Mirati’s KRAS drug adagrasib, which will be marketed as Krazati. The green light comes two days ahead of the expected …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: FDA approves Mirati's KRAS drug in non-small cell lung cancer

Kyle LaHucik

Senior Reporter

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Up­dat­ed: FDA ap­proves Mi­rati's KRAS drug in non-small cell lung can­cer

Senior Reporter

Associate Editor

Sign up to read this article for free.

Updated: FDA approves Mirati's KRAS drug in non-small cell lung cancer